SCHEMBL29966360

SCHEMBL29966360

COc1ccc2c(c1)CCC1(CCOCC1)C2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
HTR2A P28223 3/20 0.48
HTR2C P28335 3/20 0.48
HTR2B P41595 3/20 0.48
SIGMAR1 Q99720 3/20 0.48
DRD2 P14416 1/20 0.48
PRNP P04156 1/20 0.47
MALT1 Q9UDY8 2/20 0.42
METAP1 P53582 2/20 0.42
MIF P14174 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081326 0.87 SMN1; SMN2 (0.59) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL18815844 0.87 SMN1; SMN2 (0.59) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL6840784 0.83 SMN1; SMN2 (0.55) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL6795634 0.82 SMN1; SMN2 (0.56) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL6796533 0.81 SMN1; SMN2 (0.55) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL14137114 0.80 SMN1; SMN2 (0.52) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL14409344 0.78 HTR2A (0.53) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL630002 0.78 SMN1; SMN2 (0.66) SMN1; SMN2PRNPMALT1METAP1MIF
SCHEMBL629696 0.77 SMN1; SMN2 (0.58) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL11809313 0.77 SMN1; SMN2 (0.51) SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099596-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2025-03-27 US disclosed
EP-4317146-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-02-07 EP disclosed
WO-2022206737-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099596-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE CYP51A1, CYP46A1, HSD17B11 SMN1; SMN2 4387/4885HTR2A 1459/4885HTR2C 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.